Related Experiment Video
Updated: May 11, 2026
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium (DSS)
Published on: January 20, 2010
Adsorbents as antiendotoxin agents in experimental colitis
K R Gardiner1, N H Anderson, M D McCaigue
1Department of Surgery, Queen's Univesity of Belfast, Northern Ireland.
Gut
|January 1, 1993
Summary
Certain adsorbents like terra fullonica and kaolin effectively reduce systemic endotoxemia in experimental colitis. This suggests adsorbents may be a useful treatment for inflammatory bowel disease patients to control gut-derived endotoxemia.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- The intestinal barrier prevents endotoxin absorption, but is compromised in inflammatory bowel disease (IBD).
- Systemic endotoxemia, linked to IBD severity, occurs when the compromised barrier allows bacterial products into circulation.
- This study investigates adsorbent efficacy in mitigating endotoxemia in an experimental colitis model.
Purpose of the Study:
- To evaluate the effectiveness of enteral adsorbents in reducing systemic endotoxemia in a rat model of colitis.
- To compare the anti-endotoxin efficacy of terra fullonica, kaolin, and charcoal.
Main Methods:
- A hapten-induced rat model of colitis was used to induce inflammation and ulceration.
- Colitis induction was confirmed to be associated with systemic endotoxemia.
- Enteral administration of terra fullonica, kaolin, or charcoal was compared to water for their ability to reduce endotoxemia.
Main Results:
- Enteral terra fullonica and kaolin significantly reduced systemic endotoxemia compared to water.
- Charcoal administration did not significantly reduce endotoxemia.
- The efficacy of terra fullonica in controlling endotoxemia decreased with increasing colitis severity.
Conclusions:
- Enteral administration of adsorbents can control gut-derived systemic endotoxemia in experimental colitis.
- Terra fullonica and kaolin show promise as anti-endotoxin agents.
- Adsorbent therapy may be a potential treatment strategy for patients with inflammatory bowel disease.
Related Concept Videos
01:14Prevention of Further Absorption of Poison
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...